5-year outcomes from PlanB: Phase 3 trial of 21-gene Recurrence Score® result in breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the 5-year disease-free survival, defined as relapse, secondary malignancy or death, of patients with node-positive and high-risk node-negative early breast cancer who omitted adjuvant chemotherapy based on an Oncotype DX® 21-gene Recurrence Score® result of 11 or less in PlanB, a prospective phase 3 trial evaluating the Recurrence Score® result.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2016
3:17
Color/Sound

Comments are closed.